コンテンツへスキップ
Merck

1563003

USP

プロベネシド

United States Pharmacopeia (USP) Reference Standard

別名:

p-(ジプロピルスルファモイル)安息香酸

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

実験式(ヒル表記法):
C13H19NO4S
CAS番号:
分子量:
285.36
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

プロベネシド, United States Pharmacopeia (USP) Reference Standard

InChI key

DBABZHXKTCFAPX-UHFFFAOYSA-N

SMILES string

CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O

InChI

1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)

grade

pharmaceutical primary standard

API family

probenecid

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

類似した製品をお探しですか? 訪問 製品比較ガイド

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Probenecid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Probenecid and Colchicine Tablets
  • Probenecid Tablets

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

保管分類

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Probenecid and zidovudine metabolism.
Kornhauser, DavidM, et al.
Lancet, 334.8661, 473-475 (1989)
Clinical pharmacokinetics of probenecid.
Cunningham, R. F., Z. H. Israili, and P. G. Dayton.
Clinical Pharmacokinetics, 6.2, 135-151 (1981)
Nathan Robbins et al.
Cardiovascular toxicology, 12(1), 1-9 (2011-09-23)
Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used
G R Brown
Clinical pharmacokinetics, 24(4), 289-300 (1993-04-01)
The effect of concurrent probenecid administration on the pharmacokinetics of cephalosporin antibiotics varies with the available cephalosporins. Most cephalosporins are affected to some degree by concurrent probenecid administration, although ceforanide, ceftazidime, ceftriaxone and latamoxef (moxalactam) have no significant changes in
R W Cowdry et al.
Biological psychiatry, 18(11), 1287-1299 (1983-11-01)
Probenecid is used to block the transport of acid monoamine metabolites from cerebrospinal fluid (CSF), on the assumption that the resultant rise in CSF concentrations of the metabolites will reflect presynaptic "turnover" of the parent monoamine. However, CSF levels of

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)